X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2871) 2871
Book Review (292) 292
Publication (173) 173
Newsletter (43) 43
Conference Proceeding (11) 11
Magazine Article (4) 4
Book Chapter (3) 3
Dissertation (3) 3
Trade Publication Article (2) 2
Transcript (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2403) 2403
humans (2120) 2120
clarithromycin (1813) 1813
male (1368) 1368
female (1217) 1217
adult (898) 898
middle aged (829) 829
anti-bacterial agents - therapeutic use (810) 810
clarithromycin - therapeutic use (786) 786
pharmacology & pharmacy (764) 764
helicobacter pylori (667) 667
microbiology (659) 659
infection (595) 595
aged (587) 587
anti-bacterial agents - pharmacology (569) 569
helicobacter infections - drug therapy (539) 539
infectious diseases (535) 535
clarithromycin - pharmacology (508) 508
drug therapy, combination (455) 455
antibiotics (436) 436
helicobacter pylori - drug effects (427) 427
clarithromycin - administration & dosage (411) 411
microbial sensitivity tests (408) 408
treatment outcome (397) 397
anti-bacterial agents - administration & dosage (372) 372
gastroenterology & hepatology (369) 369
animals (362) 362
azithromycin (352) 352
erythromycin (328) 328
amoxicillin (323) 323
therapy (299) 299
adolescent (296) 296
infections (289) 289
eradication (277) 277
metronidazole (269) 269
helicobacter infections - microbiology (268) 268
health aspects (249) 249
abridged index medicus (242) 242
macrolides (237) 237
amoxicillin - therapeutic use (232) 232
pharmacokinetics (220) 220
anti-bacterial agents - adverse effects (217) 217
helicobacter pylori - isolation & purification (214) 214
child (213) 213
drug resistance, bacterial (213) 213
resistance (211) 211
immunology (209) 209
drug interactions (203) 203
drug therapy (200) 200
aged, 80 and over (194) 194
research (192) 192
clarithromycin - adverse effects (191) 191
analysis (189) 189
children (188) 188
prevalence (187) 187
anti-bacterial agents - pharmacokinetics (178) 178
prospective studies (175) 175
medicine & public health (173) 173
triple therapy (166) 166
in-vitro (164) 164
disease (161) 161
internal medicine (159) 159
clarithromycin - pharmacokinetics (158) 158
care and treatment (156) 156
diagnosis (156) 156
medicine, general & internal (156) 156
omeprazole (155) 155
drug resistance (154) 154
young adult (154) 154
antibiotic-resistance (152) 152
levofloxacin (152) 152
susceptibility (148) 148
antimicrobial agents (147) 147
efficacy (147) 147
helicobacter infections (146) 146
mice (146) 146
management (145) 145
drug resistance in microorganisms (144) 144
pneumonia (143) 143
administration, oral (140) 140
biopsy (140) 140
double-blind method (140) 140
drug administration schedule (136) 136
antimicrobial resistance (135) 135
omeprazole - therapeutic use (135) 135
risk factors (134) 134
antibacterial agents (133) 133
helicobacter pylori - genetics (132) 132
macrolide antibiotics (132) 132
amoxicillin - administration & dosage (131) 131
anti-ulcer agents - therapeutic use (131) 131
child, preschool (131) 131
time factors (131) 131
lansoprazole (127) 127
bacteria (125) 125
clarithromycin resistance (125) 125
dosage and administration (123) 123
respiratory system (123) 123
retrospective studies (121) 121
metronidazole - pharmacology (120) 120
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2821) 2821
Japanese (39) 39
French (16) 16
Spanish (16) 16
German (12) 12
Russian (6) 6
Chinese (3) 3
Hungarian (2) 2
Italian (1) 1
Korean (1) 1
Polish (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Critical Care, ISSN 1364-8535, 03/2017, Volume 21, Issue 1, pp. 48 - 48
Background: Failure of circulating monocytes for adequate cytokine production is a trait of sepsis-induced immunosuppression; however, its duration and... 
Sepsis | Immunosuppression | Survival | Prediction | IN-VIVO | SEPTIC SHOCK | MONOCYTES | ALPHA | HUMAN BLOOD LEUKOCYTES | CRITICAL CARE MEDICINE | Interleukin-6 - analysis | Prospective Studies | Recombinant Proteins - analysis | Granulocyte-Macrophage Colony-Stimulating Factor - analysis | Humans | Middle Aged | Survivors - statistics & numerical data | Tumor Necrosis Factor-alpha - blood | Infection - blood | Interleukin-10 - blood | Male | Gram-Negative Bacteria - metabolism | Greece | Interleukin-6 - blood | Statistics, Nonparametric | Aged, 80 and over | Placebos | Female | Interleukin-8 - blood | Interleukin-10 - analysis | Granulocyte-Macrophage Colony-Stimulating Factor - blood | Leukocytes, Mononuclear - classification | Decision Support Techniques | Logistic Models | Clarithromycin - therapeutic use | Interleukin-8 - analysis | Tumor Necrosis Factor-alpha - analysis | Recombinant Proteins - blood | Leukocytes, Mononuclear - pathology | Interferon-gamma - analysis | Gram-Negative Bacteria - pathogenicity | ROC Curve | Aged | Clarithromycin - pharmacology | Infection - complications | Interferon-gamma - blood | Prognosis | Cytokines | Blood cells | Patient outcomes | Research | Pneumonia | Intensive care | E coli | Laboratories | Mortality | Tumor necrosis factor-TNF | Infections | Gene expression | Patients | Index Medicus
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 07/2012, Volume 56, Issue 7, pp. 3819 - 3825
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2007, Volume 46, Issue 12, pp. 1039 - 1049
Objectives: We determined in vitro the potency of macrolides as P-glycoprotein inhibitors and tested in hospitalised patients whether coadministration of... 
Digoxin | Macrolides | Digitoxin | Drug interactions | P glycoprotein inhibitors | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Digitoxin, drug interactions | P glycoprotein inhibitors, drug interactions | Macrolides, drug interactions | Digoxin, drug interactions | CLARITHROMYCIN | TRANSPORT | ORAL BIOAVAILABILITY | HEART-FAILURE | PHARMACOLOGY & PHARMACY | ROXITHROMYCIN | QUINIDINE | INDUCED DIGOXIN TOXICITY | TELITHROMYCIN | DIGITOXIN | INTOXICATION | Inulin - pharmacokinetics | Digitoxin - pharmacokinetics | Heart Diseases - metabolism | Humans | Male | Alanine Transaminase - blood | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Pharmacoepidemiology - methods | Inpatients | Drug Interactions | Macrolides - pharmacokinetics | Biological Transport | Ketolides - administration & dosage | Aged, 80 and over | Inulin - administration & dosage | Female | Heart Diseases - blood | Digoxin - blood | Caco-2 Cells | Digitoxin - blood | Ketolides - pharmacokinetics | Macrolides - administration & dosage | Heart Diseases - physiopathology | Inulin - blood | Digitoxin - administration & dosage | ATP-Binding Cassette, Sub-Family B, Member 1 - physiology | Digoxin - pharmacokinetics | Erythromycin - administration & dosage | Bilirubin - blood | Erythromycin - pharmacokinetics | Aspartate Aminotransferases - blood | Digoxin - administration & dosage | Creatinine - blood | Aged | Index Medicus
Journal Article
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 2011, Volume 43, Issue 3, pp. 141 - 150
Journal Article
International Archives of Allergy and Immunology, ISSN 1018-2438, 03/2017, Volume 172, Issue 1, pp. 45 - 54
Journal Article
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 7/2018, Volume 74, Issue 7, pp. 913 - 920
Cytochrome P450 (CYP) 3A4 is responsible for the metabolism of more than 30% of clinically used drugs. Inherent between subject variability in clearance of... 
Biomedicine | Inter-racial variability | Caucasian | South Asian | Pharmacology/Toxicology | Pharmacokinetics | Inducibility | Cytochrome P450 3A4 | MESSENGER-RNA EXPRESSION | INTERINDIVIDUAL VARIABILITY | POPULATIONS | POLYMORPHISM | CYTOCHROME-P450 3A4 | GENOTYPE-PHENOTYPE ASSOCIATIONS | METABOLISM | IN-VIVO | PHARMACOLOGY & PHARMACY | MIDAZOLAM | Rifampin - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Rifampin - blood | Area Under Curve | Humans | Asian Continental Ancestry Group - genetics | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Cytochrome P-450 CYP3A Inducers - blood | Clarithromycin - blood | Young Adult | Cytochrome P-450 CYP3A - genetics | Clarithromycin - pharmacokinetics | Cytochrome P-450 CYP3A Inducers - pharmacokinetics | Adult | Continental Population Groups | European Continental Ancestry Group - genetics | Cytochrome P-450 CYP3A Inhibitors - blood | Enzyme Induction | Genotype | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A Inducers - pharmacology | Midazolam - blood | Cytochrome P-450 CYP3A - metabolism | Rifampin - pharmacology | Clarithromycin - pharmacology | Physiological aspects | Medical colleges | Rifampin | Analysis | Cytochrome P-450 | Cytochrome | Clarithromycin | Statistical analysis | Cytochrome P450 | Variability | Whites | Exposure | Males | Metabolism | Substrates | Midazolam | Genotypes | Asians | Index Medicus
Journal Article